| Property | Value |
|---|
|
?:abstract
|
-
Dexamethasone was shown to decrease the mortality in coronavirus disease-2019 (COVID-19) recently Use of corticosteroids was harmful in other coronavirus infections previously WHO recommended against routine use of corticosteroids in COVID-19 In view of these, we reviewed the evidence about the use of corticosteroids in virus-induced acute respiratory distress syndrome (ARDS) Corticosteroids are beneficial in ARDS regardless of etiology However, they increased the mortality rate in influenza-associated ARDS In SARS and the Middle East respiratory syndrome, corticosteroids increased the mortality, delayed the viral clearance and increased the length of hospital stay In the case of COVID-19, the available evidence from retrospective and observational studies is inconclusive about the corticosteroid use Low-dose therapies appear to be effective Evidence from a randomized control study found dexamethasone is effective in decreasing mortality in severe COVID-19 cases More studies are needed to validate the benefit of corticosteroids in COVID-19
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}